Annual report pursuant to Section 13 and 15(d)

Description of Business and Summary of Significant Accounting Policies - Additional Information (Detail)

v3.8.0.1
Description of Business and Summary of Significant Accounting Policies - Additional Information (Detail)
 1 Months Ended 12 Months Ended
Feb. 01, 2012
USD ($)
Oct. 10, 2001
USD ($)
shares
Dec. 31, 2005
USD ($)
Nov. 30, 2017
USD ($)
CompensationPlan
Agreement
Deliverables
Segments
shares
Nov. 30, 2016
USD ($)
Aug. 31, 2016
USD ($)
Schedule of Available-for-sale Securities [Line Items]            
Concentration risk related to supplier       Company depends on one supplier for the source of its collection kits    
Number of deliverables for revenue recognized | Deliverables       2    
Period of doubtful for accounts receivable due from client       21 years    
Contracted storage periods option two       21 years    
Contracted storage periods option one       1 year    
Contracted storage periods option three       Lifetime    
Deferred revenue recognition period       12 months    
Number of licensing agreement made by entity | Agreement       12    
Number of license agreement | Agreement       2    
Impairment on long lived assets       $ 0 $ 0  
Goodwill impairment charge         111,392 $ 1,666,430
Minimum percentage probability of realized tax benefit on settlement       50.00%    
Provisions for interest or penalties related to uncertain tax positions       $ 0 0  
Uncertain tax provisions       0 0  
Advertising cost included in selling, general and administrative expenses       1,008,000 1,186,000  
Unrealized holding losses, trading securities       (82,000) (17,000)  
Unrealized (loss) gain on marketable securities, net of tax       6,457 (135,524)  
Payment warranty     $ 50,000      
Increased payment warranty $ 75,000          
Additional payment warranty $ 10,000          
Reserves recorded under programs       $ 18,000 17,000  
Number of employee stock based compensation plan | CompensationPlan       2    
Stock-based option compensation expense       $ 972,000 1,772,000  
Employee Stock Incentive Plan [Member]            
Schedule of Available-for-sale Securities [Line Items]            
Number of outstanding options excluded from computation of diluted earnings per share | shares       22,500    
Accounts Receivable [Member]            
Schedule of Available-for-sale Securities [Line Items]            
Period of doubtful for accounts receivable due from client       30 days    
Umbilical Cord Blood and Cord Tissue Stem Cell Service and PrepaCyte-CB [Member]            
Schedule of Available-for-sale Securities [Line Items]            
Number of reportable segments | Segments       2    
PrepaCyte CB [Member]            
Schedule of Available-for-sale Securities [Line Items]            
Goodwill impairment charge         $ 1,777,822  
Saneron [Member]            
Schedule of Available-for-sale Securities [Line Items]            
Ownership interest       33.00% 33.00%  
Saneron [Member] | CCEL Bio-Therapies, Inc. [Member]            
Schedule of Available-for-sale Securities [Line Items]            
Non-Controlling interest after merger   43.42%        
Saneron Therapeutics, Inc. [Member] | CCEL Bio-Therapies, Inc. [Member]            
Schedule of Available-for-sale Securities [Line Items]            
Issue of shares by parent and another subsidiary of parent to the share holder of company merged with wholly owned subsidiary | shares   260,000        
Fair value of shares issued by parent and another subsidiary of parent to the share holder of company merged with wholly owned subsidiary   $ 1,924,000        
Saneron Therapeutics, Inc. [Member] | Stem Cell Preservation Technologies, Inc. [Member]            
Schedule of Available-for-sale Securities [Line Items]            
Issue of shares by parent and another subsidiary of parent to the share holder of company merged with wholly owned subsidiary | shares   195,000        
Fair value of shares issued by parent and another subsidiary of parent to the share holder of company merged with wholly owned subsidiary   $ 3,900